Mini-symposium & Workshop 2023

Organized by the Institute of Molecular Biosciences, Mahidol University, in collaboration with the Protein Society of Thailand and the Integrative Computational BioScience (ICBS) Center.

Click to register List of attendees Schedule and Fee More details
Prof. Sir Tom Blundell, University of Cambridge, UK

Topic: “Revolutionary Developments in the Design of New Medicines: From Computational Statistical & X-ray Experimental Methods of 1960s to AI/ML and cryoEM Approaches in the 2020s.

Professor Sir Tom Blundell is a world class expert in structural biology and drug discovery, currently at the Biomedical Campus of University of Cambridge. He has produced software for homology modelling, for example Modeller cited 13,000 times, and now also leading generative AI/ML and cryoEM packages. As pioneer of fragment-based drug discovery, co-founding Astex, now with 2 oncology drugs on the market. He founded the UK research council BBSRC and was earlier scientific advisor of the conservative PM Margaret Thatcher.

Prof. Ruben Abagyan, University of California San Diego, USA

Topic: “New Docking/AI platform to Screen Billions of Compounds for a Specific Target-Property Profile.

Prof. Ruben Abagyan is Professor of Skaggs School of Pharmacy and Pharmaceutical Sciences at the University of California San Diego. Dr. Abagyan and his group work in specialized in developing and utilizing techniques for structure-based discovery, molecular modeling, and optimization of potential drug candidates, identifying targets, large scale bioinformatics and bioinformatics. The applications include viral, cancer, neurodegeneration, parasitic, and endocrine diseases.

Asst. Prof. Duangrudee Tanramluk, Mahidol University, Thailand
Topic: “Solving Biomolecular Design Puzzles with Data-Driven Drug Discovery Platforms: MANORAA and SIMFONEE.

Dr. Duangrudee Tanramluk is an Assistant Professor in Structural Bioinformatics at Mahidol University in Thailand. She lead the development of a revolutionary AI systems for Drug Discovery: MANORAA & SIMFONEE packages. Her data-driven drug discovery platform enables in-depth and big picture analysis of small molecule drug discovery via programmable URL. Her field of expertise is on building software to decipher protein specificity and promiscuity. Her webservice fosters sustainability in drug design education and bring new hope for precision medicine.

Dr. Jiye Shi, Eli Lilly and Company, USA
Topic: “Generative AI: A Co-pilot for Drug Discovery.

Dr. Jiye Shi is the Associate Vice President, Global Head of Computational Design and Automation Platforms at Eli Lilly and Company. He is the world-class expert in AI-inspired biologics and small molecule drug discovery. His computational talents lead to the discovery of Romosozumab and Bimekizumab. He has developed novel structure-based AI/ML antibody design algorithms which led to the design of antibodies targeting a specific epitope and the design of dual-specific antibodies. He has established strong partnerships with academic and industrial partners, led to talents recruited by AI and biotech companies (e.g. DeepMind, BenevolentAI, Exscientia).

Dr. Arun Prasad Pandurangan, University of Cambridge, UK
Topic: “Protein Mutant Stability Prediction: Analyses of Drug Resistance Mutations in Infectious Diseases.

Dr Arun Prasad Pandurangan is a senior researcher at the Heart & Lung Research Institute, University of Cambridge. He is an expert in structural bioinformatics, genomics and modelling cryo-EM maps with specific interest in understanding the impacts of genetic mutations in disease and drug resistance. He is Associate Editors of BMC Bioinformatics, Computational and Structural Biotechnology Journal, etc.

Jiraporn Panmanee, Ph.D., Mahidol University, Thailand

Jiraporn Panmanee is currently a Lecturer at the Institute of Molecular Biosciences, Mahidol University. She possess a Ph.D. in Biological Sciences with research focuses on in silico structure-based drug design, neurotoxicity assessment of pesticides, structural biology, and neurobiology of neurodegenerative diseases. Her academic pursuit has focused on unraveling complexities in these domains to contribute to advancements in healthcare and environmental science.

Ittipat Meewan, Ph.D., Mahidol University, Thailand

Ittipat Meewan is Lecturer at the Institutes of Molecular Biosciences, Mahidol University. His current research focuses on computational-aided development of small molecules and peptide antivirals, targeting viruses such as SARS-CoV-2, HBV, HCV, ZIKV, DENV, and HPV. The primary techniques include molecular docking, molecular dynamics, and machine learning are employed for virtual screening of large libraries against target proteins and identify potential drug candidates which are then validated experimentally.

Academic Conference: “Mini-symposium on AI-driven Drug Discovery: The Future of Medicine”
Practical Training: “Computational Drug Discovery”

Mini-symposium on “AI-driven Drug Discovery: The Future of Medicine”
Date: Thursday, November 2, 2023
Time: 8:30 AM to 4:00 PM
Venue: Grand Ballroom, Prince Mahidol Hall Conference Center, Mahidol University (Salaya Campus)
Participants: 70–100 participants

Workshop on “Computational Drug Discovery”
Date: Friday, November 3, 2023 (1st batch)
Friday, December 1, 2023 (2nd batch)
Time: 8:30 AM to 4:00 PM
Venue: Computer Laboratory at the Institute of Molecular Biosciences Building, Mahidol University (Salaya Campus)
Participants: 20 participants in each batch